Welcome to our dedicated page for Lipella Pharmaceuticals news (Ticker: LIPO), a resource for investors and traders seeking the latest updates and insights on Lipella Pharmaceuticals stock.
Lipella Pharmaceuticals Inc (LIPO) is a clinical-stage biotechnology company pioneering advanced drug reformulations for conditions with significant unmet medical needs. Specializing in liposomal delivery technology, Lipella develops targeted therapies for complex disorders including Oral Lichen Planus and Hemorrhagic Cystitis.
This news hub provides investors and industry professionals with timely, comprehensive updates on Lipella's clinical progress, regulatory milestones, and strategic initiatives. Track developments across key areas including Phase 2 trial results, intellectual property updates, and partnership announcements.
Our curated news collection features verified press releases, clinical trial disclosures, and scientific presentations related to Lipella's pipeline candidates like LP-10 and LP-310. Stay informed about advancements in localized drug delivery systems and patent-protected innovations.
Bookmark this page for direct access to primary source materials and objective reporting on Lipella's research achievements. Regularly updated with official company communications, this resource supports informed analysis of the company's position within the competitive biopharmaceutical landscape.
Lipella Pharmaceuticals (Nasdaq: LIPO) announced a manufacturing collaboration with Cook MyoSite to support its drug candidate LP-10, aimed at treating hemorrhagic cystitis. LP-10 has received Orphan Drug Designation from the FDA and recently completed a Phase 2a clinical trial with positive results. The partnership is expected to streamline the Chemistry, Manufacturing, and Control (CMC) documentation process, crucial for regulatory approval. Dr. Michael Chancellor emphasized the importance of Cook MyoSite's expertise in GMP manufacturing for expediting clinical supplies for LP-10. The collaboration aims to address the significant unmet medical need for effective treatments for hemorrhagic cystitis.
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) announced it has successfully dosed the first patient in a human clinical trial for a novel bladder MRI contrast agent. This trial is supported by a $1.35 million Phase II Small Business Innovation Research grant from the National Institute of Diabetes and Digestive and Kidney Diseases, awarded in 2022. The proprietary ICE-MRI technology aims to improve the diagnosis of interstitial cystitis/bladder pain syndrome and bladder tumors by accurately measuring bladder permeability. The trial represents an important milestone in developing objective diagnostic tools for urological conditions.
FAQ
What is the current stock price of Lipella Pharmaceuticals (LIPO)?
What is the market cap of Lipella Pharmaceuticals (LIPO)?
